Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox CEO Keynote Speaker at UKTI Thought Leadership Conference on Dementia
September 17, 2015
Milan conference to detail progress towards earlier diagnosis and improving outcomes
Oxford, United Kingdom - Cytox Ltds CEO, Dr Richard Pither, will be a keynote speaker at UK Trade & Investments (UKTI) GREAT Week Life Sciences thought leadership conference, Dementia and UK Regenerative Medicine Landscape, in Milan on 30th September 2015. The conference runs from 28th Sept-2nd Oct, coinciding with the World Expo in Milan, and offers a combined programme in specialist life science areas.
The keynote address will be given by The Lord Dunlop, Parliamentary Under Secretary of State for Scotland and delegates will have the opportunity to attend parallel sessions on Dementia or Regenerative Medicine, led by world-renowned speakers and industry experts. The Dementia Session will detail the challenges faced in dementia treatment, the current practices to manage and improve outcomes for patients and UK innovations to ensure early detection. Delegates are invited to learn about the UKs world-class research platform for dementia treatment and prevention, progress towards earlier diagnosis, and enabling better care all underpinned by strong partnership between patients and the public and private sectors. Speakers will include Dr Eric Karran of Alzheimers Research UK, Dr Michael J. ONeill of Lilly UK, Prof John Gallacher of the University of Oxford and Dr Jill Rasmussen, GP Lead for NHS England Dementia Team, as well as Dr Richard Pither of Cytox Ltd.
Richard will discuss the challenges for a small company working in this complex disease area and the potential he sees in enabling early diagnosis in dementia in managing the disease more effectively.
Cytox has recently announced a strategic partnership with Affymetrix to develop and commercialize a blood-based genetic assay for research in diagnosis and prognosis of Alzheimers disease (AD) and Mild Cognitive Impairment (MCI). This is in addition to receiving Innovate UK funding as part of a UK consortium and recent international research collaborations.
Cytox Limited is a UK-based company with a unique scientific and proprietary technology platform, working in partnership with Affymetrix. Through the application of this fundamental science and our specific know-how, we are elucidating the biology and genetics behind dementia, as well as developing prognostic tests for cognitive decline and individual risk of developing Alzheimers disease or other dementias.
The GREAT Weeks are a series of trade missions coinciding with this years World Expo in Milan. Under the theme Grown in Britain, each mission is sector specific and represents an outstanding opportunity for UK companies to meet major buyers, potential partners and and identify overseas opportunities in a sector where UK expertise is in high demand.
Programme of activities include panel discussions, networking opportunities, 1-2-1 meetings and complimentary access to Milan Expo 2015.